Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Hepatitis

Free Subscription Articles published in J Viral Hepat Retrieve available abstracts of 239 articles: HTML format

Single Articles

November 2025
1. GONZALEZ CJ, Perez-Mejia CN, Hernandez N, Kapadia SN, et al
   Identifying Varying Influences on Eliminating Hepatitis C Across Medical Specialties.
   J Viral Hepat. 2025;32:e70093.
   PubMed     Abstract available
   
   
   
2. LAUREILLARD D, Binh NT, Vinh VH, Hong TT, et al
   High Efficiency and Safety of Hepatitis C Treatment Among People Who Inject Drugs in Vietnam.
   J Viral Hepat. 2025;32:e70090.
   PubMed     Abstract available
   
   
   
3. GHANY MG, Ward JW, Baldwin Z, Jiao S, et al
   HCV Testing and Treatment of Adults in the United States: 2014 Through 2021-Data From Two National Commercial Testing Laboratories.
   J Viral Hepat. 2025;32:e70087.
   PubMed     Abstract available
   
   
   
4. QURESHI H, Canchola JA, Hai G, Latif AQ, et al
   Evaluation of Blood Droplet Volumes on the Cobas Plasma Separation Card for HCV RNA Testing in Resource-Limited Settings.
   J Viral Hepat. 2025;32:e70091.
   PubMed     Abstract available
   
   
   October 2025
5. HANDANAGIC S, Shadaker S, BaliashvilI D, Schumacher IT, et al
   Demographic and Clinical Characteristics of Patients With Hepatitis C and Hepatitis B Co-Infection, Georgia, 2017-2023.
   J Viral Hepat. 2025;32:e70067.
   PubMed     Abstract available
   
   
   
6. HUANG D, Zhu Z, Peng J, Zhang S, et al
   Global Trends and Health Inequalities in Acute Hepatitis E Burden: A Joinpoint Regression and Cross-Country Inequality Analysis, 1990-2021.
   J Viral Hepat. 2025;32:e70073.
   PubMed     Abstract available
   
   
   
7. TORGERSEN J, Smookler D, Russell R, Gasior J, et al
   Early Read-Time Performance of the OraQuick HCV Rapid Antibody Assay for the Exclusion of HCV Viremia.
   J Viral Hepat. 2025;32:e70066.
   PubMed     Abstract available
   
   
   
8. KASSA GM, Lim AG, Tamiru MT, Alamneh TS, et al
   Risk Factors for Hepatitis C Virus Among the General Population in Sub-Saharan Africa-An Analysis of Systematic Review Data.
   J Viral Hepat. 2025;32:e70065.
   PubMed     Abstract available
   
   
   
9. CONWAY A, Grebely J, Treloar C, Matthews S, et al
   Policymaker Perspectives on the Role of Health Systems in Sustainable Hepatitis C Point-Of-Care Testing in Australia.
   J Viral Hepat. 2025;32:e70080.
   PubMed     Abstract available
   
   
   
10. AHAD M, Moussa D, Wallace J, Wade AJ, et al
    Knowledge and Perceptions of Hepatitis B in Immigrant Populations: A Systematic Review and Thematic Synthesis of Qualitative Research.
    J Viral Hepat. 2025;32:e70069.
    PubMed     Abstract available
    
    
    
11. MOHAREB AM, Ezaz G, Kim AY, Freedberg KA, et al
    Clinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure.
    J Viral Hepat. 2025;32:e70079.
    PubMed     Abstract available
    
    
    
12. ABU-DAYYEH I, Chemaitelly H, Al Tibi A, Ghunaim M, et al
    Hepatitis B Virus in Jordan: Prevalence, Incidence and Clearance From Cross-Sectional and Cohort Studies.
    J Viral Hepat. 2025;32:e70075.
    PubMed     Abstract available
    
    
    
13. TAO X, Yu W, Yan Q, Han G, et al
    Age Modifies the Association Between HBV DNA Levels and Liver Dysfunction Risk During Pregnancy.
    J Viral Hepat. 2025;32:e70074.
    PubMed     Abstract available
    
    
    
14. XIAO J, Zhang X, Mao X, Lai S, et al
    Efficacy and Safety of Velpatasvir Plus Sofosbuvir With or Without Ribavirin in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2025;32:e70078.
    PubMed     Abstract available
    
    
    
15. YING X, Ng N, Reidy D, Azari J, et al
    Prescriber Specialty Involvement in Medicare Patients With Chronic Hepatitis B.
    J Viral Hepat. 2025;32:e70070.
    PubMed     Abstract available
    
    
    
16. NATOUR RT, Haimi M, Hazan R, Saadi T, et al
    Reduced Predictive Performance of the FIB-4 Index in Chronic Hepatitis B Patients With Concurrent Metabolic Dysfunction-Associated Liver Disease.
    J Viral Hepat. 2025;32:e70071.
    PubMed     Abstract available
    
    
    
17. LUONG CL, Ellett LK, Pratt N, Staff K, et al
    Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024.
    J Viral Hepat. 2025;32:e70082.
    PubMed     Abstract available
    
    
    
18. BHATIA P, Mohd A, Katiyar H, Goel A, et al
    Longitudinal Profiles of Cytokines and Chemokines in Self-Limiting Hepatitis E.
    J Viral Hepat. 2025;32:e70088.
    PubMed     Abstract available
    
    
    
19. YAN L, Yuan M, Su M, Cui K, et al
    U-Shaped Relationship Between CT-Measured Liver-To-Spleen Volume Ratio and Mortality in HBV-ACLF Patients.
    J Viral Hepat. 2025;32:e70076.
    PubMed     Abstract available
    
    
    
20. BUGSSA G, Teklehaymanot T, Medhin G, Nayagam S, et al
    Prevalence and Factors Associated With Hepatitis B Virus Infection in Tigray Region, Northern Ethiopia.
    J Viral Hepat. 2025;32:e70077.
    PubMed     Abstract available
    
    
    
21. VOJT G, Bonnet P, Scott J, Hathorn E, et al
    Peer-Delivered Outreach With Rapid Treatment Pathways for Hepatitis C Testing and Treatment Among Unhoused People.
    J Viral Hepat. 2025;32:e70085.
    PubMed     Abstract available
    
    
    
22. ZHANG L, Ji H, Pang S, Yan Y, et al
    Identifying Adherence Trajectories in Chronic Hepatitis B: A Cluster-Based Approach to Long-Term Treatment Management.
    J Viral Hepat. 2025;32:e70068.
    PubMed     Abstract available
    
    
    
23. CHAU A, Li J, Jun DW, Hsu YC, et al
    Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide Analogs.
    J Viral Hepat. 2025;32:e70081.
    PubMed     Abstract available
    
    
    
24. WONG RJ, Yang Z, Lim J, Jou JH, et al
    High Prevalence of Cirrhosis or Hepatocellular Carcinoma at Hepatitis Delta Infection Diagnosis Reflects Alarming Delays in Testing.
    J Viral Hepat. 2025;32:e70086.
    PubMed     Abstract available
    
    
    
25. SALAMANCA BV, Johannessen A, Dalgard O, Whittaker R, et al
    Linkage to Care, Retention in Care and Treatment Uptake Among Patients Diagnosed With Chronic Hepatitis B in Norway, 2008-2022.
    J Viral Hepat. 2025;32:e70089.
    PubMed     Abstract available
    
    
    September 2025
26. WANG M, Wang Y, Yang Z, Yang C, et al
    Clinical Observational Study on HBV Reactivation After Direct-Acting Antiviral Therapy in HCV/HBV Coinfected Patients in Guizhou, China.
    J Viral Hepat. 2025;32:e70061.
    PubMed     Abstract available
    
    
    
27. BOUDOVA S, Iyer NS, Tholey DM, Fenkel JM, et al
    The Effect of HCV on Methadone Dose During Pregnancy.
    J Viral Hepat. 2025;32:e70060.
    PubMed     Abstract available
    
    
    
28. KAWAMATSU S, Rai KK, Gielen V, Patel A, et al
    Treatment Discontinuation and Adherence in Patients With Chronic Hepatitis B Infection Newly Initiating Nucleos(t)ide Analogues in Japan: A Retrospective Cohort Study.
    J Viral Hepat. 2025;32:e70062.
    PubMed     Abstract available
    
    
    
29. GREEN F, Simmons R, Leeman D, Desai M, et al
    Global Systematic Review of the Measurement of Stigma Associated With People Living With Hepatitis B or Hepatitis C Viruses.
    J Viral Hepat. 2025;32:e70064.
    PubMed     Abstract available
    
    
    
30. REMY AJ, Bellon S, Smadhi R, Bottlaender J, et al
    HCV Screening Before Endoscopy in Hepatogastroenterology Outpatient Clinic: The Depist C Endo Study.
    J Viral Hepat. 2025;32:e70063.
    PubMed     Abstract available
    
    
    August 2025
31. LI Y, Li Z, Chen R, Jia C, et al
    Global, Regional and National Burden of Chronic Hepatitis C, 1990-2021: A Systematic Analysis for the GBD Study 2021.
    J Viral Hepat. 2025;32:e70053.
    PubMed     Abstract available
    
    
    
32. HUI VW, Yang Z, Yip TC, Cheung R, et al
    Recognisable Alcohol Use Significantly Increases the Risk of Adverse Outcomes in Patients With Hepatitis B Virus-Related Cirrhosis.
    J Viral Hepat. 2025;32:e70049.
    PubMed     Abstract available
    
    
    
33. HEATH K, Guzman R, Elsum I, Wade AJ, et al
    Balancing Efficiency and Accuracy in Hepatitis C Rapid Antibody Testing: Insights From a Cluster Randomised Crossover Trial.
    J Viral Hepat. 2025;32:e70043.
    PubMed     Abstract available
    
    
    
34. GAO Y, Yang P, Guan Y, Liu P, et al
    M1-Like Macrophage May Contribute to the Inflammation and Fibrosis Process of Chronic Hepatitis B.
    J Viral Hepat. 2025;32:e70052.
    PubMed     Abstract available
    
    
    
35. SONGTANIN B, Flores J, Barba R, Saba J, et al
    Occult Hepatitis C Virus Infection: A Narrative Review.
    J Viral Hepat. 2025;32:e70051.
    PubMed     Abstract available
    
    
    
36. ANDERSON S, Gielen V, Coutinho AD, Clark L, et al
    Duration of Nucleos(t)ide Analogue Treatments in Patients With Chronic Hepatitis B Virus Infection in the United States.
    J Viral Hepat. 2025;32:e70055.
    PubMed     Abstract available
    
    
    
37. CONWAY B, Yi S, Truong D
    CHIME: Sofosbuvir/Velpatasvir (S/V) for the Treatment of HCV Infection Among Vulnerable Inner-City Residents.
    J Viral Hepat. 2025;32:e70057.
    PubMed     Abstract available
    
    
    
38. HE Q, Dong J, Huang L, Gao Y, et al
    Hepatitis E Virus Infection in Hyperbilirubinemia Patients Progressed to Liver Failure in 2003-2021, China.
    J Viral Hepat. 2025;32:e70054.
    PubMed     Abstract available
    
    
    
39. GENOWSKA A, Dobrowolska K, Zarebska-Michaluk D, Tyszko P, et al
    Trends and Socio-Demographic Patterns of Hepatitis B Virus Hospitalisations in Poland: A 12-Year Nationwide Analysis.
    J Viral Hepat. 2025;32:e70059.
    PubMed     Abstract available
    
    
    July 2025
40. ELBAZ T, Al-Naamani K, Abosheaishaa H, Alswat K, et al
    Leading Role of Sofosbuvir/Daclatasvir in Achieving Hepatitis C Elimination in Egypt.
    J Viral Hepat. 2025;32:e70032.
    PubMed     Abstract available
    
    
    
41. MAUNG ST, Chaiteerakij R
    Scoping Review on Strategies for Safe Nucleot(s)ide Analogue Discontinuation and Optimising Functional Cure in Chronic Hepatitis B.
    J Viral Hepat. 2025;32:e70040.
    PubMed     Abstract available
    
    
    
42. FREELAND C, Plunkett Q, Sirapu S, Cohen C, et al
    A Person-Centered Hepatitis B Approach Using the COM-B Model to Understand Barriers and Facilitators of Hepatitis B Testing, Management and Treatment.
    J Viral Hepat. 2025;32:e70041.
    PubMed     Abstract available
    
    
    
43. RAMIER C, Carrat F, Beo VD, Parlati L, et al
    Unhealthy Behaviours and All-Cause Mortality Among People With Chronic Hepatitis B, With and Without Hepatitis Delta (ANRS CO22 HEPATHER).
    J Viral Hepat. 2025;32:e70033.
    PubMed     Abstract available
    
    
    
44. SHIHA G, Helmy A, Mikhail N, Hassan A, et al
    Long Term Clinical Outcomes in Chronic Hepatitis C Patients Who Achieved SVR Following DAAs: A Decade Long Prospective Study.
    J Viral Hepat. 2025;32:e70044.
    PubMed     Abstract available
    
    
    
45. ADEBAJO A, Qiao S, Esu I, Olatosi B, et al
    The Efficacy and Sustainability of an Implementation Intervention (FOCUS Program) on Linkage to Hepatitis C Care Time at a Community Health Center in the Deep South: A Longitudinal Study Based on Electronic Medical Records.
    J Viral Hepat. 2025;32:e70045.
    PubMed     Abstract available
    
    
    
46. YARDENI D, Cividalli O, Itkowitz B, Lipnizkiy I, et al
    Impact of Universal Screening for HDV in HBV-Infected Patients on Chronic HDV Detection Rate in Israel.
    J Viral Hepat. 2025;32:e70046.
    PubMed     Abstract available
    
    
    
47. RAYNER D, McCullough F, McQue K, Jones K, et al
    Prospective Evaluation of Blood Borne Virus Testing in Custody Suites in North-East England.
    J Viral Hepat. 2025;32:e70042.
    PubMed     Abstract available
    
    
    
48. HU X, Wan S, Yan H, Tang M, et al
    Outcomes of Assisted Reproductive Technology in Women With Hepatitis B Infection.
    J Viral Hepat. 2025;32:e70047.
    PubMed     Abstract available
    
    
    
49. TAKAKI S, Ohya K, Mori N, Ochi H, et al
    Hepatitis C Patients Over the Age of 75 Should Be Treated With Direct-Acting Antivirals, as Their Prognosis With Treatment Is Similar to That of Uninfected Healthy Individuals of the Same Age.
    J Viral Hepat. 2025;32:e70048.
    PubMed     Abstract available
    
    
    June 2025
50. MARLOWE EM, Swanson BE, Realegeno SE, Meyer WA 3rd, et al
    Epidemiological Burden of Hepatitis Delta Virus in the United States.
    J Viral Hepat. 2025;32:e70029.
    PubMed     Abstract available
    
    
    
51. LI S, Dong W, Yu Y, Yang Z, et al
    A Government-Led, Patient-Centric Strategy to Re-Engage Diagnosed but Untreated Hepatitis C Patients in Yunnan Province, China.
    J Viral Hepat. 2025;32:e70028.
    PubMed     Abstract available
    
    
    
52. XU C, Yin DH, Han JH, Gao YN, et al
    Efficacy of Traditional Chinese Medicine External Therapies in Treating Insomnia in Patients With Chronic Hepatitis B: Systematic Review and Meta-Analysis.
    J Viral Hepat. 2025;32:e70030.
    PubMed     Abstract available
    
    
    
53. SANDMANN L, Windzio L, Bremer B, Falak S, et al
    Droplet Digital PCR: A Powerful Tool for Accurate Quantification of Hepatitis D Virus RNA Levels and Verification of Detection Limits.
    J Viral Hepat. 2025;32:e70036.
    PubMed     Abstract available
    
    
    
54. HIRODE G, Kilany M, Pi S, Kim A, et al
    Chronic Hepatitis B Patients Referred for Liver Transplantation After Nucleos(t)ide Analog Cessation.
    J Viral Hepat. 2025;32:e70031.
    PubMed     Abstract available
    
    
    
55. IACOB S, Chitul M, Stan D, Gheorghe D, et al
    Identifying Risk Factors for Hepatocellular Carcinoma in Patients With Delta Hepatitis: A Prognostic Study.
    J Viral Hepat. 2025;32:e70034.
    PubMed     Abstract available
    
    
    
56. PENG Y, Song Y, Liu X, Du X, et al
    Host Factor SRSF7 Promotes HBV Replication Through Binding to and Stabilising Viral pgRNA.
    J Viral Hepat. 2025;32:e70024.
    PubMed     Abstract available
    
    
    
57. SI NAFA SA, Benali S, Penaranda G, Deuffic-Burban S, et al
    Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study.
    J Viral Hepat. 2025;32:e70038.
    PubMed     Abstract available
    
    
    
58. MENDIZABAL M, Sabate CD, Gonzalez Ballerga E, Gruz F, et al
    Increasing Treatment Uptake for Chronic Hepatitis B in South America: A Comparative Analysis of Country-Specific and WHO 2024 Guidelines.
    J Viral Hepat. 2025;32:e70035.
    PubMed     Abstract available
    
    
    May 2025
59. WANG X, Yan X, He B, Li B, et al
    Global Burden and Trends of Acute Hepatitis C From 1990 to 2021: An Analysis Based on the 2021 Global Burden of Disease Study.
    J Viral Hepat. 2025;32:e70026.
    PubMed     Abstract available
    
    
    
60. WONG NS, Chan DP, Wong GL, Lee SS, et al
    Cost-Effectiveness of Universal Screen-and-Treat Strategies for Reducing Morbidity and Mortality of Chronic Hepatitis B in a High-Endemicity City.
    J Viral Hepat. 2025;32:e70027.
    PubMed     Abstract available
    
    
    April 2025
61. INOUE J, Minami S, Abe K, Kida M, et al
    Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues.
    J Viral Hepat. 2025;32:e70021.
    PubMed     Abstract available
    
    
    
62. VAITTINADA AYAR P, Abdelkader J, Gay M, Allali R, et al
    Systematic Screening for Hepatitis B, C, and HIV and Linkage to Care in Patients With Mental Health Disorders Admitted to the Emergency Department.
    J Viral Hepat. 2025;32:e70018.
    PubMed     Abstract available
    
    
    
63. AHMED S, Nadir MA, Farooqi HA, Ashraf H, et al
    Enhancing Hepatitis C Management: Mortality Trends and Disparities in the US by Sex, Age Group, Race/Ethnicity and Region (1999-2020).
    J Viral Hepat. 2025;32:e70011.
    PubMed     Abstract available
    
    
    
64. JIA Y, Qi X, Yu X, Dong M, et al
    Accuracy of International Guidelines in Identifying Normal Liver Histology in Chinese Patients With HBeAg-Positive Chronic HBV Infection.
    J Viral Hepat. 2025;32:e14024.
    PubMed     Abstract available
    
    
    
65. RONG X, Yang G, Xu Y, Chen H, et al
    Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First-Time HBV-Related Decompensated Cirrhosis.
    J Viral Hepat. 2025;32:e14029.
    PubMed     Abstract available
    
    
    
66. XUE K, Wen L, Ji X, Yan X, et al
    Impact of HBV Infection in Couples on In Vitro Fertilisation-Embryo Transfer Outcomes and Clinical Characteristics of Newborns: A Retrospective Study Based on 3900 Infertile Couples.
    J Viral Hepat. 2025;32:e70015.
    PubMed     Abstract available
    
    
    
67. AN W, Li M, Luo J, Yu Z, et al
    Prognosis of Acute HEV Infection in Patients With Liver Cirrhosis: A Retrospective Study of 628 Chinese Patients.
    J Viral Hepat. 2025;32:e14018.
    PubMed     Abstract available
    
    
    
68. SUN J, Kelly M, Tsheten T, Pourmarzi D, et al
    Prevalence of Hepatitis C Among Migrants: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2025;32:e70025.
    PubMed     Abstract available
    
    
    
69. HARDTKE S, Yurdaydin C, Caruntu FA, Curescu MG, et al
    Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection.
    J Viral Hepat. 2025;32:e70022.
    PubMed     Abstract available
    
    
    
70. LIANG H, Zheng X, Liu Y, Mao Q, et al
    Effects of Different Antiviral Treatments on Liver Inflammation and Fibrosis in Patients With Chronic Hepatitis B.
    J Viral Hepat. 2025;32:e70019.
    PubMed     Abstract available
    
    
    
71. HUI RW, Wong DK, Mak LY, Fung J, et al
    Development and Validation of a High-Sensitivity Droplet Digital PCR Assay for Serum Hepatitis B Virus DNA Detection.
    J Viral Hepat. 2025;32:e70023.
    PubMed     Abstract available
    
    
    
72. POWELL AA, Costella A, Roche R, Leeman D, et al
    Sensitivity Analysis of Hepatitis B and C Mortality in England Using Data Linkage: Meeting the WHO Elimination Threshold for Mortality.
    J Viral Hepat. 2025;32:e70016.
    PubMed     Abstract available
    
    
    March 2025
73. BARRE T, Ramier C, Ory K, Saidi T, et al
    Liver Enzyme Elevation After Hepatitis C Virus Cure: Is There a Sex Effect? (ANRS CO13 HEPAVIH Cohort).
    J Viral Hepat. 2025;32:e70007.
    PubMed    
    
    
    
74. EILARD A, Ringlander J, Andersson ME, Nilsson S, et al
    Long-Term Outcome of Chronic Hepatitis B-Histological Score and Viral Genotype Are Important Predictors of Hepatocellular Carcinoma.
    J Viral Hepat. 2025;32:e70008.
    PubMed     Abstract available
    
    
    
75. PARK C, Hwang G, Choi WM, Han JE, et al
    Baseline Alpha-Fetoprotein Elevation and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B: A Multicentre Cohort Study.
    J Viral Hepat. 2025;32:e70006.
    PubMed     Abstract available
    
    
    
76. KOGIAS D, Gavriilidis E, Antoniadou C, Skeva A, et al
    Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab.
    J Viral Hepat. 2025;32:e70005.
    PubMed     Abstract available
    
    
    
77. CHELOUAH S, Nna H, Angijiro P, Thomas F, et al
    Screening, Prevalence and Management of Chronic Viral Hepatitis C in Mental Health Setting: Towards the Eradication of A Forgotten Reservoir.
    J Viral Hepat. 2025;32:e70014.
    PubMed     Abstract available
    
    
    
78. WANG H, Xu C, Yao R, Zhang W, et al
    Single-Cell Transcriptome Identifies a Proinflammatory B-Cell Subset in Hepatitis B Virus Associated Acute-on-Chronic Liver Failure.
    J Viral Hepat. 2025;32:e70012.
    PubMed     Abstract available
    
    
    
79. ZOU H, Zhu L, Cao L, Suo S, et al
    Vertical Transmission in Mothers Taking TAF With Exceptionally High Viral Load.
    J Viral Hepat. 2025;32:e70000.
    PubMed     Abstract available
    
    
    
80. JUON HS, Yang D, Fang CX, Hann HW, et al
    Perceived HBV-Related Stigma Is Associated With Lower Antiviral Medication Adherence in Patients With Chronic Hepatitis B.
    J Viral Hepat. 2025;32:e70010.
    PubMed     Abstract available
    
    
    
81. ZHANG Y, Jin D, Zhu H, Lin M, et al
    Hepatocytes and Hepatic Stellate Cells Carry Different Levels of DNA Damage due to Their Sensitivity to Oxidative Stress in Chronic Hepatitis B.
    J Viral Hepat. 2025;32:e70017.
    PubMed     Abstract available
    
    
    February 2025
82. WANG H, Wang J, Zhang S, Zhang S, et al
    Clinical Features and Transition of Acute Hepatitis B Virus Infection.
    J Viral Hepat. 2025;32:e14048.
    PubMed     Abstract available
    
    
    
83. ZHANG Z, Wang J, Zhu L, Li Y, et al
    Optimization of the Use of APRI and FIB-4 for Ruling Out Liver Cirrhosis in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase.
    J Viral Hepat. 2025;32:e14057.
    PubMed     Abstract available
    
    
    
84. EMERY H, Evans C, Jack K, Martello E, et al
    A Qualitative Systematic Review of Barriers and Facilitators to Hepatitis B and C Programmes in Prisons.
    J Viral Hepat. 2025;32:e14049.
    PubMed     Abstract available
    
    
    
85. MUTIMER D, Brown M, Logan J, Kelgeri C, et al
    Patient Source of Referral Is a Key Determinant of Subsequent Retention in Care for Young Chronic Hepatitis B Patients.
    J Viral Hepat. 2025;32:e14059.
    PubMed     Abstract available
    
    
    
86. PERERA H, Imsirovic H, Macphail G, Webster D, et al
    Resistance-Associated Substitution Testing Trends and Impact on HCV Treatment Outcomes in Canada: A CanHepC-CANUHC Analysis.
    J Viral Hepat. 2025;32:e14058.
    PubMed     Abstract available
    
    
    
87. SINGAL AG, Reddy KR, Colombo M, Morris HL, et al
    DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.
    J Viral Hepat. 2025;32:e14056.
    PubMed     Abstract available
    
    
    
88. HILTON B, De Angelis D, Mitchell H, Harris R, et al
    Heterogeneity in Risk and Implications for Hepatitis C Reinfection in People Who Inject Drugs in England.
    J Viral Hepat. 2025;32:e14052.
    PubMed     Abstract available
    
    
    
89. VOELLER AS, Johannessen A, Abebe ZZ, Adugna W, et al
    The Disease and Economic Burden of HBV and HCV in Ethiopia.
    J Viral Hepat. 2025;32:e14053.
    PubMed     Abstract available
    
    
    
90. GU Y, Gu L, Chen L, Li J, et al
    Immunotherapy Using HBV Vaccine Pulsed DCs and Induced T-Cells Combined Antiviral Drugs in Treatment Naive CHB Patients-A Multi-Centre Phase II Study.
    J Viral Hepat. 2025;32:e14045.
    PubMed     Abstract available
    
    
    
91. FURQUIM D'ALMEIDA A, Ho E, Govaerts L, Michielsen P, et al
    Severe Liver-Related Outcomes in Patients With Hepatitis Delta: Results From a Multi-Ethnic Multicenter Long-Term Follow-Up Study.
    J Viral Hepat. 2025;32:1-15.
    PubMed     Abstract available
    
    
    
92. ONG E, Xia T, Laing R, Richmond JA, et al
    Australian Community Pharmacists' Preparedness to Offer and Discuss Hepatitis C Testing and Treatment With Pharmacy Clients: A Representative Cross-Sectional Survey.
    J Viral Hepat. 2025;32:e70001.
    PubMed     Abstract available
    
    
    
93. RAMRAKHIANI H, Le MH, Kam L, Nguyen B, et al
    Long-Term Immunity and Anamnestic Response Following Hepatitis B Vaccination: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2025;32:e70003.
    PubMed     Abstract available
    
    
    
94. UKAGEBU CJ, Alao JO, Bamigboye FO, Ukaegbu JC, et al
    Evaluating Hepatitis B Screening During Pregnancy: A Study on Diagnostic Accuracy and Infection Control in Nigeria.
    J Viral Hepat. 2025;32:e70002.
    PubMed     Abstract available
    
    
    
95. MENNINI FS, Sciattella P, Simonelli C, Marcellusi A, et al
    Long-Term Effects of Direct-Acting Antivirals on Hepatitis C: Trends in Liver Disease-Related Hospitalisations in Italy.
    J Viral Hepat. 2025;32:e14061.
    PubMed     Abstract available
    
    
    
96. ELGRETLI W, Shengir M, Sasson S, Ramanakumar AV, et al
    Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors.
    J Viral Hepat. 2025;32:e70004.
    PubMed     Abstract available
    
    
    
97. TAN X, Xun L, Yin Q, Chen C, et al
    Epigenetic Modifications in HBV-Related Hepatocellular Carcinoma.
    J Viral Hepat. 2025;32:e14044.
    PubMed     Abstract available
    
    
    January 2025
98. QURESHI M
    A Health Systems Strengthening Approach to Address the High Burden of Hepatitis C in Pakistan.
    J Viral Hepat. 2025;32:e14050.
    PubMed     Abstract available
    
    
    
99. SAID SS, Shadaker S, McMahon BJ, Armstrong PA, et al
    Hepatitis B Care and Treatment in Zanzibar, Tanzania: A Demonstration Project Following 2015 WHO Treatment Guidelines, 2017-2021.
    J Viral Hepat. 2025;32:e14051.
    PubMed     Abstract available
    
    
    
100. WANG B, Wang X, Xiao L, Xian J, et al
     Misuse of the Lower Limit of Detection in HBV DNA Testing and Anti-HBe Positive Status Will Significantly Impact the Diagnosis of Occult HBV Infection.
     J Viral Hepat. 2025;32:e14046.
     PubMed     Abstract available
     
     
     
101. CAUSSE X, Potier P, Valery A, Labadie H, et al
     Predictive Factors for HBsAg Loss in Chronic HBeAg-Negative Hepatitis B Virus Infection: Insights From a 5-Year French Cohort.
     J Viral Hepat. 2025;32:e14041.
     PubMed     Abstract available
     
     
     
102. LI M, Hunt B, Balani B, Ogedegbe C, et al
     A US-Based Multi-Site Pilot to Screen Hepatitis B Surface Antigen-Positive Patients for Hepatitis D.
     J Viral Hepat. 2025;32:e14043.
     PubMed     Abstract available
     
     
     
103. TSAI YN, Lo JC, Tseng CH, Hsieh SC, et al
     Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy.
     J Viral Hepat. 2025;32:1-8.
     PubMed     Abstract available
     
     
     
104. SAWALMEH A, Johansson EW, Kostas D, Hjaijeh D, et al
     Hepatitis B Patients' Adherence to Treatment in Relation to Knowledge, Attitudes, and Practices (KAP) in the West Bank, Palestine, 2022-2023.
     J Viral Hepat. 2025;32:e14055.
     PubMed     Abstract available
     
     
     
105. POOROLAJAL J, Shadi Y, Heshmati B
     Interaction Between Hepatitis B, Hepatitis C and Alcohol in the Development of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
     J Viral Hepat. 2025;32:e14042.
     PubMed     Abstract available
     
     
     
106. PARLAR YE, Gulnar MO, Kirmizigul B, Gencdal G, et al
     The Course of COVID-19 Infection in Patients With Chronic Hepatitis Delta.
     J Viral Hepat. 2025;32:e14054.
     PubMed     Abstract available
     
     
     December 2024
107. BERTOLETTI A
     The immune response in chronic HBV infection.
     J Viral Hepat. 2024;31 Suppl 2:43-55.
     PubMed     Abstract available
     
     
     
108. VO-QUANG E, Lemoine M
     Global elimination of HBV: Is it really achievable?
     J Viral Hepat. 2024;31 Suppl 2.
     PubMed     Abstract available
     
     
     
109. LIM YS
     Treatment decisions based on HBV DNA.
     J Viral Hepat. 2024;31 Suppl 2:36-42.
     PubMed     Abstract available
     
     
     November 2024
110. PARK Y, Heo J, Kang D, Gwak GY, et al
     Impact of Maternal Hepatitis B Virus Infection on Congenital Heart Disease Risk in Offspring: A National Cohort Study.
     J Viral Hepat. 2024 Nov 26. doi: 10.1111/jvh.14036.
     PubMed     Abstract available
     
     
     
111. ROSECRANS A, Harris R, Clair AS, Rice M, et al
     Challenges and Opportunities for Treating Hepatitis C Amongst People Who Use Drugs: Experience of an Integrated Mobile Clinic in Baltimore City.
     J Viral Hepat. 2024 Nov 26. doi: 10.1111/jvh.14038.
     PubMed     Abstract available
     
     
     
112. YEW KC, Sim ASY, Hawkins R, Acharyya S, et al
     Real-World Evaluation of Point-of-Care Testing for Hepatitis C Antibodies: Navigating Hepatitis C Elimination Effort.
     J Viral Hepat. 2024 Nov 22. doi: 10.1111/jvh.14039.
     PubMed     Abstract available
     
     
     
113. KASSA GM, Weldemariam AG, Abrahim SA, French CE, et al
     Seroprevalence of Hepatitis C in Ethiopia: First National Study Based on the 2016 Ethiopian Demographic and Health Survey.
     J Viral Hepat. 2024 Nov 21. doi: 10.1111/jvh.14037.
     PubMed     Abstract available
     
     
     
114. FURL R, Scarsi KK, Sayles H, Anderson M, et al
     Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income Countries.
     J Viral Hepat. 2024 Nov 15. doi: 10.1111/jvh.14031.
     PubMed     Abstract available
     
     
     
115. ANDANI A, Mellou K, Dewda P, Eeuwijk J, et al
     Evolution and Impact of Hepatitis A Epidemiology in Europe-Systematic Literature Review of the Last 20 Years.
     J Viral Hepat. 2024 Nov 11. doi: 10.1111/jvh.14030.
     PubMed     Abstract available
     
     
     
116. WONG GL
     Updated Guidelines for the Prevention and Management of Chronic Hepatitis B-World Health Organization 2024 Compared With China 2022 HBV Guidelines.
     J Viral Hepat. 2024 Nov 6. doi: 10.1111/jvh.14032.
     PubMed     Abstract available
     
     
     
117. DIRKS M, Hennemann AK, Grosse GM, Beer A, et al
     Long-Term Follow-Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon-Free and Interferon-Based Hepatitis C Virus Treatment.
     J Viral Hepat. 2024 Nov 6. doi: 10.1111/jvh.14033.
     PubMed     Abstract available
     
     
     
118. DAS S, Sood V, Rastogi A, Agarwal N, et al
     Clinico-Pathological Spectrum of Hepatitis A Virus-Induced Autoimmune-Like Hepatitis in Children.
     J Viral Hepat. 2024 Nov 1. doi: 10.1111/jvh.14028.
     PubMed     Abstract available
     
     
     October 2024
119. ETOORI D, Cococcia S, Srivastava A, Flanagan S, et al
     The Camden and Islington Viral Hepatitis Identification Tool (CIVHIT): Use of a Clinical Database Case-Finding Tool for Hepatitis B, Hepatitis C and HIV in Primary Care.
     J Viral Hepat. 2024 Oct 24. doi: 10.1111/jvh.14027.
     PubMed     Abstract available
     
     
     
120. ALI I, Muhammad S, Naqvi SSZH, Wei L, et al
     Hepatitis B Virus-Associated Liver Carcinoma: The Role of Iron Metabolism and Its Modulation.
     J Viral Hepat. 2024 Oct 24. doi: 10.1111/jvh.14016.
     PubMed     Abstract available
     
     
     
121. GINNANE JF, Scott N, Radley A, Dillon JF, et al
     Cost-Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in Australia.
     J Viral Hepat. 2024 Oct 23. doi: 10.1111/jvh.14015.
     PubMed     Abstract available
     
     
     
122. MARTIN MT, Hietpas AR, Novak JL, Deming P, et al
     A National Survey of Pharmacist Involvement in Hepatitis C Virus Management in the United States.
     J Viral Hepat. 2024 Oct 22. doi: 10.1111/jvh.14014.
     PubMed     Abstract available
     
     
     
123. YI S, Wiesmann C, Truong D, Sharma S, et al
     Community Pop-Up Clinic: Cascade of Care and HCV Treatment of Vancouver's Inner-City PWID Populations.
     J Viral Hepat. 2024 Oct 19. doi: 10.1111/jvh.14023.
     PubMed     Abstract available
     
     
     
124. OHLENDORF V, Wubbolding M, Honer Zu Siederdissen C, Bremer B, et al
     Limited Value of HBV-RNA for Relapse Prediction After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative Hepatitis B Patients.
     J Viral Hepat. 2024 Oct 19. doi: 10.1111/jvh.14026.
     PubMed     Abstract available
     
     
     
125. SIMMONS R, Harris R, Lim AG, Leeman D, et al
     Estimating Prevalence and Number of People With Chronic Hepatitis B: A Multiplier Method Based on Public Health Surveillance Data in UK (2015-2021).
     J Viral Hepat. 2024 Oct 16. doi: 10.1111/jvh.14019.
     PubMed     Abstract available
     
     
     
126. IWADARE T, Kimura T, Sugiura A, Okumura T, et al
     Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy.
     J Viral Hepat. 2024 Oct 15. doi: 10.1111/jvh.14025.
     PubMed     Abstract available
     
     
     
127. BALIASHVILI D, Merabishvili T, Tskhomelidze I, Tsereteli M, et al
     Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia.
     J Viral Hepat. 2024 Oct 14. doi: 10.1111/jvh.14022.
     PubMed     Abstract available
     
     
     
128. ZAKALASHVILI M, Surguladze S, Baliashvili D, Zarkua J, et al
     Evaluation of Knowledge, Attitudes and Practices for Hepatitis B Virus Infection Among Primary Healthcare Physicians in Georgia.
     J Viral Hepat. 2024 Oct 10. doi: 10.1111/jvh.14011.
     PubMed     Abstract available
     
     
     
129. BUTT AA, Yan P, Iwnetu R, Malik AA, et al
     Hepatitis Delta Coinfection Rates and All-Cause Mortality Among Hepatitis B-Infected Veterans in the USA.
     J Viral Hepat. 2024 Oct 9. doi: 10.1111/jvh.14021.
     PubMed     Abstract available
     
     
     
130. CHEN Y, Zhang X, Yan X, Wang L, et al
     A Programme of Hepatitis C Surveillance With Active Linkage to Care (HEAL) for Inpatients in Two Tertiary Hospitals in Jiangsu, China.
     J Viral Hepat. 2024 Oct 9. doi: 10.1111/jvh.14020.
     PubMed     Abstract available
     
     
     
131. LU Z, Sun YM, Chen S, Meng T, et al
     Multiple Low-Level Viraemia Suggest Hindered Liver Fibrosis Regression in Chronic Hepatitis B Patients During Antiviral Therapy.
     J Viral Hepat. 2024 Oct 7. doi: 10.1111/jvh.14012.
     PubMed     Abstract available
     
     
     
132. PHAW NA, Rayner D, Johnson A, Thompson C, et al
     Harm Minimisation and Other Preventative Measures Must Improve to Reduce Transmission of Hepatitis C in Prisons.
     J Viral Hepat. 2024 Oct 7. doi: 10.1111/jvh.14017.
     PubMed    
     
     
     
133. BULDUKOGLU OC, Ocal S, Cekin AH
     Disparities in the Detection, Diagnosing and Treatment of Hepatitis B Among Females.
     J Viral Hepat. 2024 Oct 5. doi: 10.1111/jvh.14013.
     PubMed    
     
     
     
134. WAN Y, Yin S, Wu C
     Reply: Regarding the Predictive Role of CXCL16 in Liver Inflammation in Chronic Hepatitis B Patients.
     J Viral Hepat. 2024 Oct 5. doi: 10.1111/jvh.13996.
     PubMed    
     
     
     
135. ZHANG HL, Nemeth H, Woodhouse EW, Davenport CA, et al
     Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure.
     J Viral Hepat. 2024 Oct 3. doi: 10.1111/jvh.14009.
     PubMed     Abstract available
     
     
     
136. PATEL P, Wells MT, Wethington E, Shapiro M, et al
     United States Provider Experiences With Telemedicine for Hepatitis C Treatment: A Nationwide Survey.
     J Viral Hepat. 2024 Oct 1. doi: 10.1111/jvh.14010.
     PubMed     Abstract available
     
     
     
137. MAKUZA JD, Wong S, Morrow RL, Binka M, et al
     Impact of COVID-19 pandemic on hepatocellular carcinoma surveillance in British Columbia, Canada: An interrupted time series study.
     J Viral Hepat. 2024;31:592-600.
     PubMed     Abstract available
     
     
     September 2024
138. TULENKO SE, Ngimbi P, Mwandagalirwa K, Tabala M, et al
     Immunogenicity of a Birth Dose of Hepatitis B Vaccine in Kinshasa, Democratic Republic of Congo: A Randomised, Controlled Trial.
     J Viral Hepat. 2024 Sep 24. doi: 10.1111/jvh.14003.
     PubMed     Abstract available
     
     
     
139. ZOVICH B, Patel P, Tu T, Wang S, et al
     Perspectives of People Living With Chronic Hepatitis D: Impact of Disease and Unmet Needs Along the Care Cascade.
     J Viral Hepat. 2024 Sep 17. doi: 10.1111/jvh.14005.
     PubMed     Abstract available
     
     
     
140. SONG Y, Chen H, Li J, Zhong F, et al
     Lower Serum Albumin Level: A Prospective Risk Predictor of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection.
     J Viral Hepat. 2024 Sep 16. doi: 10.1111/jvh.14008.
     PubMed     Abstract available
     
     
     
141. LIANG LY, Yip TC, Lai JC, Lam AS, et al
     Dynamic Changes in ELF Score Predict Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Antiviral Treatment.
     J Viral Hepat. 2024 Sep 10. doi: 10.1111/jvh.14004.
     PubMed     Abstract available
     
     
     
142. BARRE T, Parlati L, Bourliere M, Ramier C, et al
     Socioeconomic Deprivation Weighs Heavily on Liver Fibrosis and Mortality After Hepatitis C Cure (ANRS CO22 Hepather).
     J Viral Hepat. 2024 Sep 10. doi: 10.1111/jvh.14006.
     PubMed     Abstract available
     
     
     
143. KWOK TY, Hui RW, Mao X, Ling GS, et al
     Cigarette Smoking Is Associated With Lower Chance of Hepatitis B Surface Antigen Seroclearance and Altered Host Immunity.
     J Viral Hepat. 2024 Sep 9. doi: 10.1111/jvh.14007.
     PubMed     Abstract available
     
     
     
144. GRANTZ KH, Cepeda J, Astemborski J, Kirk GD, et al
     Individual Heterogeneity and Trends in Hepatitis C Infection Risk Among People Who Inject Drugs: A Longitudinal Analysis.
     J Viral Hepat. 2024 Sep 5. doi: 10.1111/jvh.13999.
     PubMed     Abstract available
     
     
     
145. HOFMEISTER MG, Ly KN, Yin S, Spradling PR, et al
     Evolving Characteristics of Decedents With Hepatitis A Listed as a Cause of Death, United States, 2011-2021.
     J Viral Hepat. 2024 Sep 3. doi: 10.1111/jvh.14002.
     PubMed     Abstract available
     
     
     August 2024
146. PAK K, Ibrahim B, Saab S
     Safety of Tenofovir Disoproxil Fumarate Among Breastfeeding Infants of Patients With Chronic Hepatitis B: A Systematic Review.
     J Viral Hepat. 2024 Aug 29. doi: 10.1111/jvh.14001.
     PubMed     Abstract available
     
     
     
147. MAHAJAN A, Kharawala S, Desai S, Kendrick S, et al
     Association of Hepatitis B Surface Antigen Levels With Long-Term Complications in Chronic Hepatitis B Virus Infection: A Systematic Literature Review.
     J Viral Hepat. 2024 Aug 16. doi: 10.1111/jvh.13988.
     PubMed     Abstract available
     
     
     
148. SACHAR Y, Congly SE, Burak KW, Manko A, et al
     Epidemiology, Treatment Patterns and Survival in Canadian Patients With Chronic Hepatitis B-Related Hepatocellular Carcinoma.
     J Viral Hepat. 2024 Aug 16. doi: 10.1111/jvh.13989.
     PubMed     Abstract available
     
     
     
149. WEI B, Li H, Cheng M, Yang Y, et al
     NLRP3 Inflammasome Activation Mediates Hepatitis E Virus-Induced Neuroinflammation.
     J Viral Hepat. 2024 Aug 13. doi: 10.1111/jvh.13998.
     PubMed     Abstract available
     
     
     
150. THORNTON KA, Deming PD, Archer GRD, Ceniceros JA, et al
     Expanding Hepatitis C Virus Treatment in the New Mexico State Prison System: Using the ECHO Model for Provider and Prison Peer Education.
     J Viral Hepat. 2024 Aug 13. doi: 10.1111/jvh.13997.
     PubMed     Abstract available
     
     
     
151. IMSIROVIC H, Macphail G, Conway B, Fraser C, et al
     Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis.
     J Viral Hepat. 2024 Aug 12. doi: 10.1111/jvh.13995.
     PubMed     Abstract available
     
     
     
152. WASUWANICH P, Wen TS, Egerman RS, Karnsakul W, et al
     Epidemiology and Outcomes of Hepatitis E Virus-Associated Hospitalisations in the United States With a Focus on Pregnancy: A Nationwide Population Study, 1998-2020.
     J Viral Hepat. 2024 Aug 11. doi: 10.1111/jvh.13994.
     PubMed     Abstract available
     
     
     
153. CAVIGLIA GP, Casalone E, Olivero A, Birolo G, et al
     MiRNome Profiling of Circulating Extracellular Vesicles in Patients With Chronic Hepatitis D Undergoing Pegylated Interferon Alpha Treatment.
     J Viral Hepat. 2024 Aug 11. doi: 10.1111/jvh.14000.
     PubMed     Abstract available
     
     
     
154. EL EKIABY M, Tanaka J, van Drimmelen H, Allain JP, et al
     Infectivity of Hepatitis B Virus Surface Antigen-Positive Plasma With Undetectable HBV-DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?
     J Viral Hepat. 2024 Aug 10. doi: 10.1111/jvh.13990.
     PubMed     Abstract available
     
     
     
155. RUPASINGHE D, Choi JY, Kumarasamy N, Pujari S, et al
     Post-Diagnosis HCV RNA Testing Rates Prior to HCV Treatment Among People Living With HIV With HCV Antibody Positivity in the Asia-Pacific Region.
     J Viral Hepat. 2024 Aug 8. doi: 10.1111/jvh.13993.
     PubMed     Abstract available
     
     
     
156. PATEL NH, Lucko A, Vachon A, Doucette KE, et al
     Assessment of HBV variants and novel viral and immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated steatotic liver disease.
     J Viral Hepat. 2024 Aug 7. doi: 10.1111/jvh.13979.
     PubMed     Abstract available
     
     
     
157. HAMA SA, Sirwan R, Abubakr M, Ahmed GS, et al
     Clinical Prevalence of Hepatitis D Virus Among Hepatitis B Patients in Sulaymaniyah Governorate, Northern Iraq.
     J Viral Hepat. 2024 Aug 7. doi: 10.1111/jvh.13987.
     PubMed     Abstract available
     
     
     
158. FLISIAK R, Zarebska-Michaluk D, Janczewska E, Parfieniuk-Kowerda A, et al
     Sustained Virological Response After Early Discontinuation of Hepatitis C Treatment.
     J Viral Hepat. 2024 Aug 7. doi: 10.1111/jvh.13991.
     PubMed     Abstract available
     
     
     
159. WONG RJ, Liao M, Chen Y, Kwan M, et al
     Outcomes of a 1-Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B.
     J Viral Hepat. 2024 Aug 5. doi: 10.1111/jvh.13992.
     PubMed     Abstract available
     
     
     July 2024
160. YENDEWA GA, Salata RA, Olasehinde T, Mulindwa F, et al
     Self-reported hepatitis B testing among noninstitutionalized adults in the United States before the implementation of universal screening, 2013-2017: A nationwide population-based study.
     J Viral Hepat. 2024 Jul 30. doi: 10.1111/jvh.13985.
     PubMed     Abstract available
     
     
     
161. STASI C, Pacifici M, Puglia M, Voller F, et al
     Severe acute hepatitis of unknown origin in children: Is it still a mystery? What role does adenovirus play?
     J Viral Hepat. 2024 Jul 29. doi: 10.1111/jvh.13978.
     PubMed     Abstract available
     
     
     
162. TRAMONTI FANTOZZI MP, Ceccarelli L, Petri D, De Vita E, et al
     Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID-19 pandemic.
     J Viral Hepat. 2024 Jul 27. doi: 10.1111/jvh.13983.
     PubMed     Abstract available
     
     
     
163. ALAMNEH TS, Walker JG, Lim AG, Alam E, et al
     Changes in the prevalence of hepatitis B and C viral infections in Sindh province, Pakistan: Findings from two sero-surveys in 2007 and 2019.
     J Viral Hepat. 2024 Jul 26. doi: 10.1111/jvh.13986.
     PubMed     Abstract available
     
     
     
164. CHEN B, Iqbal U, Desai SK, Gries J, et al
     The role of treatment of hepatitis C with direct-acting antiviral agents on glycaemic control in diabetic patients: An updated systematic review and meta-analysis.
     J Viral Hepat. 2024 Jul 24. doi: 10.1111/jvh.13984.
     PubMed     Abstract available
     
     
     
165. HUTTON DW, Toy M, Yang D, Zhang H, et al
     Modelling the potential impact of global hepatitis B vaccination on the burden of chronic hepatitis B in the United States.
     J Viral Hepat. 2024 Jul 22. doi: 10.1111/jvh.13982.
     PubMed     Abstract available
     
     
     
166. BEYDOUN HA, Tsai J
     Screening rates for hepatitis B and C among low-income US veterans: Data from the National Veteran Homeless and Other Poverty Experiences Study.
     J Viral Hepat. 2024 Jul 10. doi: 10.1111/jvh.13981.
     PubMed     Abstract available
     
     
     
167. HUANG D, Lai H, Zhu Z, Yu H, et al
     Inverse relationship between HBV DNA levels and liver histopathological changes in immune-tolerant CHB patients.
     J Viral Hepat. 2024;31:363-371.
     PubMed     Abstract available
     
     
     June 2024
168. ZHANG J, Zhang Y
     Regarding the predictive role of CXCL16 in liver inflammation in chronic hepatitis B patients.
     J Viral Hepat. 2024 Jun 10. doi: 10.1111/jvh.13976.
     PubMed    
     
     
     
169. LI T, Chen Y, Zhang Y, Wu S, et al
     Elevated hepatitis B virus RNA levels in HBeAg-positive patients with low-level viraemia or previous low-level viraemia.
     J Viral Hepat. 2024 Jun 10. doi: 10.1111/jvh.13957.
     PubMed     Abstract available
     
     
     
170. COSTE M, Diouf A, Ndong C, Diouf A, et al
     Investigating linkage to care following community-based screening for hepatitis B virus in rural Senegal: A mixed methods study.
     J Viral Hepat. 2024 Jun 5. doi: 10.1111/jvh.13977.
     PubMed     Abstract available
     
     
     
171. CLIPMAN SJ, Mehta SH, Mohapatra S, Srikrishnan AK, et al
     Network-based strategies to combat HCV: Examining social and spatial drivers of transmission among PWID in New Delhi.
     J Viral Hepat. 2024 Jun 4. doi: 10.1111/jvh.13960.
     PubMed     Abstract available
     
     
     
172. MOUSAVI S, Alavi M, Delavari A, Poustchi H, et al
     Towards hepatitis C virus elimination in Iran: A blueprint for comprehensive strategies.
     J Viral Hepat. 2024 Jun 3. doi: 10.1111/jvh.13975.
     PubMed     Abstract available
     
     
     May 2024
173. KHAN N, Kakakhel S, Malik A, Nigar K, et al
     Genetic substructure and host-specific natural selection trend across vaccine-candidate ORF-2 capsid protein of hepatitis-E virus.
     J Viral Hepat. 2024 May 28. doi: 10.1111/jvh.13959.
     PubMed     Abstract available
     
     
     
174. DOWNS LO, Kabagambe K, Williams S, Waddilove E, et al
     Peer support for people living with hepatitis B virus-A foundation for treatment expansion.
     J Viral Hepat. 2024 May 26. doi: 10.1111/jvh.13952.
     PubMed     Abstract available
     
     
     
175. SHAYAN NA, Rahimi A, Stranges S, Thind A, et al
     Factors affecting quality of life in hepatitis B patients in Herat, Afghanistan: A case-control study.
     J Viral Hepat. 2024 May 24. doi: 10.1111/jvh.13961.
     PubMed     Abstract available
     
     
     
176. KOCHAKSARAEI GS, Yang F, Seow CH, Barkema HW, et al
     Epidemiology, linkage to care and natural history of women of childbearing age with chronic hepatitis B: A population-based study.
     J Viral Hepat. 2024 May 21. doi: 10.1111/jvh.13954.
     PubMed     Abstract available
     
     
     
177. GU Q, Yin S, Tong X, Rui F, et al
     Current research insights into the role of CTLA-4 in hepatitis B virus (HBV) infection.
     J Viral Hepat. 2024 May 21. doi: 10.1111/jvh.13958.
     PubMed     Abstract available
     
     
     
178. QURESHI H, Mahmood H, Nasir Z, Siddique S, et al
     A novel test and treat program for hepatitis C virus infection utilizing HCV core antigen testing, among police and general population, Islamabad, Pakistan, 2022.
     J Viral Hepat. 2024 May 21. doi: 10.1111/jvh.13953.
     PubMed     Abstract available
     
     
     
179. LE GUILLOU-GUILLEMETTE H, Pivert A, ElBara A, Vall M, et al
     Prevalence, clinical and virological characteristics and short-term prognosis of hepatitis delta infection among patients with HIV/HBV in Nouakchott, Mauritania.
     J Viral Hepat. 2024 May 21. doi: 10.1111/jvh.13950.
     PubMed     Abstract available
     
     
     
180. IRVIN R, Landry G, Jones MR, James A, et al
     High prevalence of hepatitis C virus infection among incarcerated persons: Results from the Louisiana Hepatitis C Elimination Plan's opt-out testing program in prisons.
     J Viral Hepat. 2024 May 17. doi: 10.1111/jvh.13941.
     PubMed     Abstract available
     
     
     
181. MESZAROS M, Coursier S, Nagot N, Moulis L, et al
     Screening for hepatitis C virus at the time of mammography using rapid diagnostic tests in women aged between 50 and 74 years (Mamm'OC NCT05067374).
     J Viral Hepat. 2024 May 15. doi: 10.1111/jvh.13947.
     PubMed     Abstract available
     
     
     
182. ROUSSOS S, Bagos C, Angelopoulos T, Chaikalis S, et al
     Incidence of primary hepatitis C infection among people who inject drugs during 2012-2020 in Athens, Greece.
     J Viral Hepat. 2024 May 14. doi: 10.1111/jvh.13951.
     PubMed     Abstract available
     
     
     
183. ZHONG W, Zheng J, Yao N, Feng Y, et al
     Association of HBeAg decline rate from mid-pregnancy to delivery with HBeAg seroconversion after delivery in hepatitis B virus-infected mothers.
     J Viral Hepat. 2024 May 10. doi: 10.1111/jvh.13948.
     PubMed     Abstract available
     
     
     
184. KUMAR A, Sahu U, Agnihotri G, Dixit A, et al
     A novel multi-epitope peptide vaccine candidate targeting hepatitis E virus: An in silico approach.
     J Viral Hepat. 2024 May 10. doi: 10.1111/jvh.13949.
     PubMed     Abstract available
     
     
     
185. MAK LY, Yee LJ, Wong RJ, Ramers CB, et al
     Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase.
     J Viral Hepat. 2024 May 8. doi: 10.1111/jvh.13914.
     PubMed     Abstract available
     
     
     
186. RAZAVI-SHEARER D
     The economic argument for hepatitis B treatment simplification and expansion.
     J Viral Hepat. 2024 May 8. doi: 10.1111/jvh.13920.
     PubMed     Abstract available
     
     
     April 2024
187. ALI M, Tucker JD, Kpokiri EE, Wu D, et al
     Crowdsourcing to increase hepatitis B and C testing and reduce hepatitis stigma among medical students in Bangladesh.
     J Viral Hepat. 2024 Apr 28. doi: 10.1111/jvh.13945.
     PubMed     Abstract available
     
     
     
188. HOLT B, Mendoza J, Nguyen H, Doan D, et al
     Barriers and enablers to people-centred viral hepatitis care in Vietnam and the Philippines: Results of a patient journey mapping study.
     J Viral Hepat. 2024 Apr 23. doi: 10.1111/jvh.13944.
     PubMed     Abstract available
     
     
     
189. ALQAHTANI SA, Yilmaz Y, El-Kassas M, Alswat K, et al
     Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt.
     J Viral Hepat. 2024 Apr 15. doi: 10.1111/jvh.13935.
     PubMed     Abstract available
     
     
     
190. WONG RJ, Hirode G, Feld J, Wong SS, et al
     An updated assessment of hepatitis delta prevalence among adults in Canada: A meta-analysis.
     J Viral Hepat. 2024 Apr 15. doi: 10.1111/jvh.13939.
     PubMed     Abstract available
     
     
     
191. OLTMANNS C, Bremer B, Kusche L, Stal P, et al
     Elevation of S2-bound alpha1-acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma.
     J Viral Hepat. 2024 Apr 12. doi: 10.1111/jvh.13943.
     PubMed     Abstract available
     
     
     
192. RUI F, Garcia E, Hu X, Ni W, et al
     Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta-analysis.
     J Viral Hepat. 2024 Apr 8. doi: 10.1111/jvh.13942.
     PubMed     Abstract available
     
     
     
193. SARAVANAN S, Shankar EM, Vignesh R, Ganesh PS, et al
     Occult hepatitis B virus infection and current perspectives on global WHO 2030 eradication.
     J Viral Hepat. 2024 Apr 5. doi: 10.1111/jvh.13928.
     PubMed     Abstract available
     
     
     
194. MAINA A, Foster GR
     Hepatitis after gene therapy, what are the possible causes?
     J Viral Hepat. 2024;31 Suppl 1:14-20.
     PubMed     Abstract available
     
     
     March 2024
195. GUPTA N, Swindells S, Scarsi KK, Furl R, et al
     Preferences and feasibility of long-acting technologies for treatment of hepatitis C virus in low- and middle-income countries: A survey of providers and policymakers.
     J Viral Hepat. 2024 Mar 28. doi: 10.1111/jvh.13921.
     PubMed     Abstract available
     
     
     
196. NAVEED A, Khalid A, Janjua N, Cloherty GA, et al
     Performance of HCV core antigen and PCR testing in a predominantly genotype 3 population.
     J Viral Hepat. 2024 Mar 14. doi: 10.1111/jvh.13937.
     PubMed     Abstract available
     
     
     
197. DOBROWOLSKA K, Pawlowska M, Zarebska-Michaluk D, Rzymski P, et al
     Direct-acting antivirals in women of reproductive age infected with hepatitis C virus.
     J Viral Hepat. 2024 Mar 14. doi: 10.1111/jvh.13936.
     PubMed     Abstract available
     
     
     
198. HAVENS JR, Lofwall MR, Young AM, Staton M, et al
     Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community.
     J Viral Hepat. 2024 Mar 4. doi: 10.1111/jvh.13933.
     PubMed     Abstract available
     
     
     
199. SULKOWSKI MS, Martinez A, Tyson GL, Scholz K, et al
     Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs.
     J Viral Hepat. 2024 Mar 3. doi: 10.1111/jvh.13927.
     PubMed     Abstract available
     
     
     February 2024
200. KATCHER JG, Klassen AC, Hann HW, Chang M, et al
     Racial discrimination, knowledge, and health outcomes: The mediating role of hepatitis B-related stigma among patients with chronic hepatitis B.
     J Viral Hepat. 2024 Feb 26. doi: 10.1111/jvh.13932.
     PubMed     Abstract available
     
     
     
201. IQBAL HS, Gunaratne MP, Loeb TA, Pradeep A, et al
     High prevalence of hepatitis B virus among MSM living with HIV in India.
     J Viral Hepat. 2024 Feb 22. doi: 10.1111/jvh.13929.
     PubMed     Abstract available
     
     
     
202. WOLFSON-STOFKO B, Hirode G, Vanderhoff A, Karkada J, et al
     Real-world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada.
     J Viral Hepat. 2024 Feb 22. doi: 10.1111/jvh.13931.
     PubMed     Abstract available
     
     
     
203. FRYE K, Davis A, Darby R, McDaniel K, et al
     A contactless cure: Leveraging telehealth to improve hepatitis C treatment at a safety-net hospital.
     J Viral Hepat. 2024 Feb 18. doi: 10.1111/jvh.13913.
     PubMed     Abstract available
     
     
     
204. WALTER LA, Prados M, Lloyd A, Sontheimer S, et al
     Birth cohort-specific consideration in an Emergency Department Hepatitis C Testing Programme: A description of age-related characteristics and outcomes.
     J Viral Hepat. 2024 Feb 17. doi: 10.1111/jvh.13930.
     PubMed     Abstract available
     
     
     
205. TULLY DC, Power KA, Sarette J, Stopka TJ, et al
     Validation of dried blood spots for capturing hepatitis C virus diversity for genomic surveillance.
     J Viral Hepat. 2024 Feb 16. doi: 10.1111/jvh.13924.
     PubMed     Abstract available
     
     
     
206. WU L, Yang Z, Zheng M
     Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos(t)ide analogues therapy.
     J Viral Hepat. 2024 Feb 8. doi: 10.1111/jvh.13926.
     PubMed     Abstract available
     
     
     
207. EPSTEIN RL, Buzzee B, White LF, Feld JJ, et al
     Test characteristics for combining non-invasive liver fibrosis staging modalities in individuals with Hepatitis C virus.
     J Viral Hepat. 2024 Feb 7. doi: 10.1111/jvh.13925.
     PubMed     Abstract available
     
     
     
208. LV R, Lu Y, Xiang W, Meng M, et al
     Chronic viral hepatitis C micro-elimination program using telemedicine in Guigang city.
     J Viral Hepat. 2024 Feb 7. doi: 10.1111/jvh.13922.
     PubMed     Abstract available
     
     
     January 2024
209. FARAG MS, van Campenhout MJH, Sonneveld MJ, Fung S, et al
     Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study).
     J Viral Hepat. 2024 Jan 19. doi: 10.1111/jvh.13918.
     PubMed     Abstract available
     
     
     
210. POLLOCK TS, Robert CA, Seybold DJ, Hur M, et al
     Prevalence of hepatitis C among pregnant women in an Appalachian population.
     J Viral Hepat. 2024 Jan 18. doi: 10.1111/jvh.13911.
     PubMed     Abstract available
     
     
     
211. QIN W, Shao L, Wang J, Zhang H, et al
     Persistence of antibodies 5 years after hepatitis B vaccination in preterm birth children: A retrospective cohort study using real-world data.
     J Viral Hepat. 2024 Jan 18. doi: 10.1111/jvh.13908.
     PubMed     Abstract available
     
     
     
212. HIBBERT M, Simmons R, Sabin CA, Mandal S, et al
     Identifying missed opportunities for hepatitis C virus antenatal testing and diagnosis in England.
     J Viral Hepat. 2024 Jan 4. doi: 10.1111/jvh.13906.
     PubMed     Abstract available
     
     
     
213. QURESHI H, Duran AC, Mahmood H, Sarwar Z, et al
     Context-dependent accuracy of the cobas plasma separation card for HCV RNA viral load measurement.
     J Viral Hepat. 2024 Jan 2. doi: 10.1111/jvh.13910.
     PubMed     Abstract available
     
     
     
214. HIGE S, Aoki K, Nakamoto D, Flaherty JF, et al
     Real-world safety and effectiveness of tenofovir alamenamide for 144 weeks in Japanese patients with chronic hepatitis B.
     J Viral Hepat. 2024 Jan 1. doi: 10.1111/jvh.13912.
     PubMed     Abstract available
     
     
     December 2023
215. ALQAHTANI SA, Stepanova M, Al Shabeeb R, Eberly KL, et al
     The impact of hepatitis B and C positive serologies on the outcomes of non-hepatic solid organ transplantation in the United States.
     J Viral Hepat. 2023 Dec 29. doi: 10.1111/jvh.13916.
     PubMed     Abstract available
     
     
     
216. O'KEEFE D, Jacka D, Douglass C, Gunn J, et al
     Distribution of rapid HCV antibody self-test kits via needle/syringe dispensing machines: Implementation and evaluation of the Vend-C pilot study in Melbourne, Australia.
     J Viral Hepat. 2023 Dec 29. doi: 10.1111/jvh.13909.
     PubMed     Abstract available
     
     
     
217. TOYODA H, Koshiyama Y, Yasuda S, Kumada T, et al
     Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection.
     J Viral Hepat. 2023 Dec 26. doi: 10.1111/jvh.13907.
     PubMed     Abstract available
     
     
     
218. WAN Y, Mao M, Li M, Liu J, et al
     Serum CXCL16: A new predictor of liver inflammation in patients with chronic hepatitis B.
     J Viral Hepat. 2023 Dec 25. doi: 10.1111/jvh.13905.
     PubMed     Abstract available
     
     
     
219. ZHOU S, Qi K, Bersoff-Matcha SJ, Mishra P, et al
     Sex-related difference analyses of efficacy and safety in clinical trials of direct-acting antivirals to treat chronic HCV genotype 1 and 3 infections.
     J Viral Hepat. 2023 Dec 19. doi: 10.1111/jvh.13901.
     PubMed     Abstract available
     
     
     
220. YANG Q, Lin T, Zhao Y, Qiu Y, et al
     International disease burden of acute viral hepatitis among adolescents and young adults: An observational study.
     J Viral Hepat. 2023 Dec 8. doi: 10.1111/jvh.13903.
     PubMed     Abstract available
     
     
     
221. WASUWANICH P, So JM, Rajborirug S, Karnsakul W, et al
     Hepatitis A hospitalisations in the United States and risk factors for inpatient mortality: A nationwide population study, 1998-2020.
     J Viral Hepat. 2023 Dec 8. doi: 10.1111/jvh.13902.
     PubMed     Abstract available
     
     
     
222. RAZAVI H, Blach S, Bregenzer A, Bruggmann P, et al
     Assessing the hepatitis C epidemiology in Switzerland: It is not that trivial.
     J Viral Hepat. 2023 Dec 8. doi: 10.1111/jvh.13904.
     PubMed    
     
     
     
223. NING Q, Yang T, Guo X, Huang Y, et al
     CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes.
     J Viral Hepat. 2023;30:951-958.
     PubMed     Abstract available
     
     
     November 2023
224. O'SULLIVAN M, Jones AM, Mourad A, Haddadin Y, et al
     Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated-Test-stage Treat study final outcomes.
     J Viral Hepat. 2023 Nov 28. doi: 10.1111/jvh.13897.
     PubMed     Abstract available
     
     
     
225. DEMIREL A, Uraz S, Deniz Z, Daglilar E, et al
     Epidemiology of hepatitis D virus infection in Europe: Is it vanishing?
     J Viral Hepat. 2023 Nov 14. doi: 10.1111/jvh.13899.
     PubMed     Abstract available
     
     
     
226. HAJARIZADEH B, Carson JM, Byrne M, Grebely J, et al
     Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
     J Viral Hepat. 2023 Nov 7. doi: 10.1111/jvh.13895.
     PubMed     Abstract available
     
     
     
227. NATOUR RT, Midlej A, Mahajna E, Kopelman Y, et al
     Chronic hepatitis B beyond clinical burden: Psychosocial effects and impact on quality of life.
     J Viral Hepat. 2023 Nov 3. doi: 10.1111/jvh.13894.
     PubMed     Abstract available
     
     
     
228. TRELOAR C, Rance J, Bryant J, Lafferty L, et al
     "There's too much power in this number. It's freaking the whole response out": the views of key informants on evidence and targets to achieve hepatitis C elimination goals in Australia.
     J Viral Hepat. 2023 Nov 2. doi: 10.1111/jvh.13896.
     PubMed     Abstract available
     
     
     October 2023
229. MAK LY, Koffas A, Dolman GE, Saleh H, et al
     Role of HBsAg levels in guiding hepatitis B virus prophylaxis in pregnancy: Insights from a multi-ethnic cohort.
     J Viral Hepat. 2023 Oct 26. doi: 10.1111/jvh.13893.
     PubMed     Abstract available
     
     
     
230. BERTISCH B, Schaetti C, Schmid P, Peter L, et al
     Chronic hepatitis C virus infections in Switzerland in 2020: Lower than expected and suggesting achievement of WHO elimination targets.
     J Viral Hepat. 2023 Oct 7. doi: 10.1111/jvh.13892.
     PubMed    
     
     
     
231. VANWOLLEGHEM T, Armstrong PA, Buti M, FitzSimons D, et al
     The elimination of hepatitis D as a public health problem: Needs and challenges.
     J Viral Hepat. 2023 Oct 3. doi: 10.1111/jvh.13891.
     PubMed     Abstract available
     
     
     
232. VIRTUDAZO MCC, Aquino JB, Arellano RNB, Fortes RA, et al
     The role of dried blood spot tests in the detection of hepatitis B infection: A systematic review.
     J Viral Hepat. 2023 Oct 3. doi: 10.1111/jvh.13890.
     PubMed     Abstract available
     
     
     
233. BEGHIN J, Meier-Stephenson V
     Does hepatitis delta virus have a preference for hepatitis B virus genotype? A systematic review of the literature.
     J Viral Hepat. 2023 Oct 3. doi: 10.1111/jvh.13889.
     PubMed     Abstract available
     
     
     September 2023
234. MA NZ, Dai W, Bao X, Bu ZQ, et al
     Effects of hepatitis B virus infection on the treatment outcomes following in vitro fertilization/intracytoplasmic sperm injection: An analysis of 21,999 first embryo transfer cycles.
     J Viral Hepat. 2023 Sep 23. doi: 10.1111/jvh.13878.
     PubMed     Abstract available
     
     
     
235. EVANS KN, Vettese T, Wortley PM, Gandhi AP, et al
     HIV and HCV testing at clinical encounters among people who inject drugs, 2013-2018-Opportunities for increased testing and prevention.
     J Viral Hepat. 2023 Sep 19. doi: 10.1111/jvh.13877.
     PubMed     Abstract available
     
     
     
236. HE H, Wu Y, Jia Z, Xu H, et al
     Risk-stratified approach by aMAP score for community population infected with hepatitis B and C to guide subsequent liver cancer screening practice: A cohort study with 10-year follow-up.
     J Viral Hepat. 2023 Sep 18. doi: 10.1111/jvh.13884.
     PubMed     Abstract available
     
     
     
237. CAROLINE A, Kate M, Roberts M, Ryan J, et al
     What is the impact of a Hepatitis C 'test, trace and treat' pilot using peer workers?
     J Viral Hepat. 2023 Sep 18. doi: 10.1111/jvh.13888.
     PubMed     Abstract available
     
     
     
238. JOHNSON A, Shearer J, Thompson C, Jelley R, et al
     Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
     J Viral Hepat. 2023 Sep 12. doi: 10.1111/jvh.13887.
     PubMed     Abstract available
     
     
     
239. KHAN S, Kumar Y, Sharma C, Gupta SK, et al
     Dysregulated metabolites and lipids in serum of patients with acute hepatitis E: A longitudinal study.
     J Viral Hepat. 2023 Sep 11. doi: 10.1111/jvh.13885.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.